Wells Fargo
ACOR

Wells Fargo’s Acorda Therapeutics ACOR Stock Holding History

Wells Fargo’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,736
Closed -$49.4K – 7763
2024
Q1 		$49.4K Sell
3,736
-5
-0.1% -$73 ﹤0.01% 5256
2023
Q4 		$56.5K Buy
3,741
+1
+0% +$11 ﹤0.01% 5226
2023
Q3 		$56.1K Hold
3,740
– – ﹤0.01% 5123
2023
Q2 		$48.7K Buy
3,740
+2
+0.1% +$24 ﹤0.01% 5438
2023
Q1 		$43.8K Buy
3,738
+1
+0% +$17 ﹤0.01% 5229
2022
Q4 		$57.3K Hold
3,737
– – ﹤0.01% 4795
2022
Q3 		$22K Buy
3,737
+3
+0.1% +$25 ﹤0.01% 5359
2022
Q2 		$35K Buy
3,734
+1,240
+50% +$22K ﹤0.01% 5192
2022
Q1 		$80K Hold
2,494
– – ﹤0.01% 5432
2021
Q4 		$119K Buy
2,494
+2,484
+24,840% +$171K ﹤0.01% 5541
2021
Q3 		$1K Hold
10
– – ﹤0.01% 6863
2021
Q2 		$1K Hold
10
– – ﹤0.01% 6795
2021
Q1 		$1K Sell
10
-279
-97% -$34.3K ﹤0.01% 6803
2020
Q4 		$24K Sell
289
-821
-74% -$75.5K ﹤0.01% 5817
2020
Q3 		$68K Buy
1,110
+203
+22% +$15.3K ﹤0.01% 5400
2020
Q2 		$81K Sell
907
-102
-10% -$10.8K ﹤0.01% 5322
2020
Q1 		$113K Buy
1,009
+160
+19% +$31.5K ﹤0.01% 5002
2019
Q4 		$207K Sell
849
-14
-2% -$3.53K ﹤0.01% 4936
2019
Q3 		$297K Buy
863
+177
+26% +$96.2K ﹤0.01% 4729
2019
Q2 		$631K Sell
686
-99
-13% -$122K ﹤0.01% 4225
2019
Q1 		$1.25M Buy
785
+137
+21% +$247K ﹤0.01% 3712
2018
Q4 		$1.21M Buy
648
+53
+9% +$115K ﹤0.01% 3696
2018
Q3 		$1.4M Sell
595
-15
-2% -$46.4K ﹤0.01% 3705
2018
Q2 		$2.1M Sell
610
-266
-30% -$814K ﹤0.01% 3421
2018
Q1 		$2.48M Buy
876
+79
+10% +$237K ﹤0.01% 3209
2017
Q4 		$2.05M Buy
797
+86
+12% +$244K ﹤0.01% 3355
2017
Q3 		$2.02M Buy
711
+6
+0.9% +$15.8K ﹤0.01% 3307
2017
Q2 		$1.67M Buy
705
+284
+67% +$563K ﹤0.01% 3347
2017
Q1 		$1.06M Sell
421
-29
-6% -$83.5K ﹤0.01% 3706
2016
Q4 		$1.02M Sell
450
-64
-12% -$152K ﹤0.01% 3680
2016
Q3 		$1.29M Sell
514
-45
-8% -$134K ﹤0.01% 3299
2016
Q2 		$1.71M Sell
559
-46
-8% -$150K ﹤0.01% 3081
2016
Q1 		$1.92M Buy
605
+18
+3% +$74.7K ﹤0.01% 2953
2015
Q4 		$3.01M Sell
587
-4
-0.7% -$17.5K ﹤0.01% 2681
2015
Q3 		$1.88M Sell
591
-41
-6% -$159K ﹤0.01% 3043
2015
Q2 		$2.53M Sell
632
-145
-19% -$560K ﹤0.01% 2919
2015
Q1 		$3.1M Sell
777
-28
-3% -$128K ﹤0.01% 2722
2014
Q4 		$3.95M Sell
805
-34
-4% -$146K ﹤0.01% 2518
2014
Q3 		$3.41M Buy
839
+38
+5% +$143K ﹤0.01% 2618
2014
Q2 		$3.24M Sell
801
-122
-13% -$497K ﹤0.01% 2660
2014
Q1 		$4.2M Sell
923
-294
-24% -$1.19M ﹤0.01% 2436
2013
Q4 		$4.26M Sell
1,217
-437
-26% -$1.7M ﹤0.01% 2369
2013
Q3 		$6.79M Buy
1,654
+287
+21% +$1.24M ﹤0.01% 1952
2013
Q2 		$5.41M Buy
+1,367
New +$5.63M ﹤0.01% 2061

Other funds holding ACOR

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo's ACOR Position: Q2 2024 in Review

Wells Fargo sold out of Acorda Therapeutics (ACOR) in Q2 2024, closing a stake of 3,736 shares — an estimated $49.4K sold.

Wells Fargo first reported a position in ACOR in Q2 2013 and held it in 44 quarters. The position peaked at $6.79M in Q3 2013. 2 funds tracked by Wall St. Rank hold ACOR as of Q2 2024.

  • Wells Fargo reported no remaining Acorda Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 3,736 Acorda Therapeutics shares in Q2 2024, an estimated $49.4K.
  • Wells Fargo first reported a position in Acorda Therapeutics in Q2 2013 and held it in 44 quarters.
  • Wells Fargo's Acorda Therapeutics position peaked at $6.79M in Q3 2013.
  • 2 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.